Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy

Journal of Drug Delivery Science and Technology

Volumn 19, Issue 1, 2009, Pages 3-14

  Palombo, M S ^a   Singh, Y ^a   Sinko, P J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Anti viral; Conjugate; Fosamprenavir; HIV; Nanocarrier; Prodrug; Targeted drug delivery; Tenofovir disoproxil fumarate

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MACROGOL; MARAVIROC; NANOCARRIER; NELFINAVIR; NEVIRAPINE; NOVIR; RALTEGRAVIR; RITONAVIR; SALZENTRY; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; BRAIN; CD4+ T LYMPHOCYTE; CELL INVASION; CELL SURFACE; DNA LIBRARY; DNA REPLICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ERADICATION THERAPY; FOLLICULAR DENDRITIC CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INTESTINE LYMPHATIC TISSUE; LIFE CYCLE; LIPOPHILICITY; LYMPHOID TISSUE; MACROPHAGE; PLASMA CONCENTRATION-TIME CURVE; PROGENY; REPEATED DRUG DOSE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE DRUG DOSE; TARGET CELL; TESTIS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PARTICLE;

EID: 59849092368     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(09)50001-9     Document Type: Review

References (103)

1. Joint United Nations Programme on HIV/AIDS and The World Health Organization-2007 AIDS epidemic update.-(2007)-http://www.unaids.org/en/ KnowledgeCentre/Resources/Publications/-2007_epiupdate_en.pdf -Accessed [June 11, 2008]
2. Joint United Nations Programme on HIV/AIDS and The World Health Organization-2006 report on the global AIDS epidemic. -(2006) http://www.unaids.org/en/KnowledgeCentre/Resources/Publications/ -[June 11, 2008]
3. Merson M. -The HIV-AIDS pandemic at 25-the global response. -N. Engl. J. Med., 354, 2414-2417, 2006.
4. Piot P., Bartos M., Ghys P., Walker N., Schwartlander B. - The global impact of HIV/AIDS. - Nature, 410, 968-973, 2001.
5. Flexner C. - HIV drug development: the next 25 years. - Nat. Rev. Drug Discov., 6, 959-965, 2007.
6. Janssen P., Lewi P., Arnold E., Daeyaert F., De Jong M., Heeres J., Koymans L., Vinkers M., Guillemont J., Pasquier E., Kukla M., Ludovici D., Andries K., De Bethune M., Pauwels R., Das K., Clark A., Frenkel Y., Hughes S., Medaer B., De Knaep F., Bohets H., De Clerck F., Lampo A., Williams P., Stoffels P. - In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-4-4-[(1E)-2-cyanoethenyl]-2,6-dimethyphenyl] amino]-2-pyrimidinyl]amino]benzonitrile (R278474), Rilpivirine). - J. Med. Chem., 48, 1901-1909, 2005.
7. Struble K., Murray J., Cheng B., Gegeny T., Miller V., Gulick R. - Antiretroviral therapies for treatment-experienced patients: current status and research challenges. - AIDS, 19, 747-756, 2005.
8. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Jarvinen T., Savolainen J. - Prodrugs: design and clinical applications. - Nat. Rev. Drug Discov., 7, 255-269, 2008.
9. Hammer S., Saag M., Schechter M., Montaner J., Schooley R., Jacobsen D., Thompson M., Carpenter C., Fischl M., Gazzard B., Gatell J., Hirsch M., Katzenstein D., Richman D., Vella S., Yeni P., Volberdine P. - Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. - JAMA, 296, 827-843, 2006.
10. Clercq E. DE - Strategies in the design of antiviral drugs. - Nat. Rev. Drug Discov., 1, 13-25, 2002.
11. Huang C., Tang M., Zhang M., Majeed S., Montabana E., Stanfield R., Dimitrov D., Korber B., Sodroski J., Wilson I., Wyatt R., Kwong P. - Structure of V3-containing HIV-1 gp120 core. - Science, 310, 1025-1028, 2005.
12. Chen L., Pei G., Zhang W. - An overall picture of chemokine receptors: basic research and drug development. - Curr. Pharm. Des., 10, 1045-1055, 2004.
13. Schols D. - HIV co-receptors as targets for antiviral therapy. - Curr. Top. Med. Chem., 4, 883-893, 2004.
14. Lusso P. - HIV and the chemokine system: 10 years later. - EMBO J., 25, 447-456, 2006.
15. Kazmierski W., Kenakin T., Gudmundsson K. - Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5, and CXCR4. - Chem. Bio. Drug Des., 67, 13-26, 2006.
16. De Clercq E. -The design of drugs for HIV and HCV - Nat. Rev. Drug Discov., 6, 1001-1017, 2007.
17. Pommier Y., Johnson A., Marchand C. - Integrase inhibitors to treat HIV/ AIDS. - Nat. Rev. Drug Discov., 4, 236-248, 2005.
18. Louis J., Clore G., Gronenborn A. - Autoprocessing of HIV-1 protease is tightly coupled to protein folding. - Nat. Struct. Biol., 6, 868-875, 1999.
19. Pomerantz R. - Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. - Clin. Infect. Dis., 34, 91-97, 2002.
20. Reiner S. - Development in motion: helper T cells at work. - Cell, 129, 33-36, 2007.
21. Cohen J. - Back-to-basics push as HIV prevention struggles. - Science, 319, 888, 2008.
22. Ahsan F., Rivas I., Khan M., Suarez A. - Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. - J. Control. Release, 79, 29-40, 2002.
23. + T cell demographics and dynamics in lymphatic tissues. - Annu. Rev. Immunol., 17, 1999.
24. Blankson J., Persaud D., Siliciano R. - The challenge of viral reservoirs in HIV-1 infection. - Annu. Rev. Med., 53, 557-593, 2002.
25. Aquaro S., Calio R., Balzarini J., Bellocchi M., Garaci E., Perno C. - Macrophages and HIV infection: therapeutic approaches toward this strategic virus reservoir. - Antiviral Res., 55, 209-225, 2002.
26. Kedzierska K., Crowe S., Turville S., Cunningham A. - The influence of cytokines, chemokines, and their receptors on HIV-1 replication in monocytes and macrophages. - Rev. Med. Virol., 13, 39-56, 2003.
27. Burton G., Keele B., Estes J., Thacker T., Gartner S. - Follicular dendritic cell contributions to HIV pathogenesis - Immunology, 14, 275-284, 2002.
28. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. - Nat, Med., 5, 512-517, 1999.
29. Su Y., Sinko P. - Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it? - Expert Opin. Drug Deliv., 3, 419-435, 2006.
30. Wu D., Clement J. - Love blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat. - Brain Res., 791, 313-316, 1998.
31. Park S., Sinko P. - P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. - J. Pharmacol. Exp. Ther., 312, 1249-1256, 2005.
32. Kim R. - Drugs as P-glycoprotein substrates, inhibitors, and inducers. - Drug Metab. Rev., 34, 47-54, 2002.
33. Temsamani J., Vidal P - The use of cell-penetrating peptides for drug delivery - Drug Discov. Today, 9, 1012-1019, 2004.
34. Gump J., Dowdy S. - TAT transduction: the molecular mechanism and therapeutic prospects. - Trends Mol. Med., 13, 443-448, 2007.
35. Shehu-Xhilaga M., De Krester D., Dejucq-Rainsford N., Hedger M. - Standing in the way of eradication: HIV-1 infection and treatment in the male genital tract. - Curr. HIV Res., 3, 345-359, 2005.
36. Thomson Healthcare Inc.- Mayo Clinic.com: Fosamprenavir (Oral Route)-(http://www.mayoclinic.com/health/drug-information/DR601699 - Accessed [June 19, 2008].
37. Chapman T., Plosker G., Perry C. - Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. - Drugs, 64, 2101-2124, 2004.
38. Wire M., Shelton M., Studenberg S. - Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. - Clin. Pharmacokinet., 45, 137-168, 2006.
39. Glaxosmithkline - Lexvia (fosamprenavir calcium) Tablets and Oral Suspension.-(http://us.gsk.com/products/assets/us_lexiva.pdf -Accessed [June 19, 2008].
40. Furfine E., Baker C., Hale M., Reynolds D., Salisbury J., Searle A., Studenberg S., Todd D., Tung R., Spaltenstein A. - Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. - Antimicrob. Agents Chemother., 48, 791-798, 2004.
41. Studenberg S., Furfine E., Boehlert C. et al. - Mechanism of absorption of GW433908, the phosphate prodrug of the HIV protease inhibitor amprenavir-HIV DART 2004, Montego Bay, Jamaica, Dec 12-16, 2004.
42. Wood R., Arasteh K., Stellbrink H., Teofilo E., Raffi F., Pollard R., Eron J., Yeo J., Millard J., Wire M., Naderer O. - Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients - Antimicrob. Agents Chemother., 48, 124-129, 2004.
43. Polli J., Jarrett J., Studenberg S., Humphreys J., Dennis S., Brouwer K., Woolley J. - Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. - Pharm. Res., 16, 1999.
44. Sadler B., Chittick G., Polk R., Slain D., Kerkering T., Studenberg S., Lou Y., Moore K., Woolley J. - Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single dose to healthy male subjects. - J. Clin. Pharmacol., 41, 386-396, 2001.
45. Wire M., Lou Y., Shelton M., et al. - Evaluation of plasma amprenavir formulations with a high fat breakfast (HFB, APV10008).-44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, Oct 3 - Nov. 2, 2004.
46. Garraffo R., Lavrut T., Heripret I., Serini M., Carsenti H., Durant J., Dellmonica P. - Fosamprenavir (FPV) through concentrations (Cmin) and inhibitory quotients (IQ), at steady-state, in plasma and lymphocytes of HIV infected patients receiving different dosage regimens. - 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec City, Canada, Apr 28-30, 2005.
47. Chaudry N., Eron J., Naderer O., Pereira A., Wire M., Fiscus S., Kashuba A. - Effects of formulation and dosing strategy on amprenavir concentrations in seminal plasma of human immunodeficiency virus type-1 infected men. - Clin. Infect. Dis., 35, 760-762, 2002.
48. Fung H., Stone E., Piacenti F. - Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. - Clin. Ther., 24, 1515-1548, 2002.
49. Chapman T, McGavin J., Noble S. - Tenofovir disoproxil fumarate. - Drugs, 63, 1597-1608, 2003.
50. Gilead Sciences INC. - Viread (tenofovir disoproxil fumarate) tablets: US package insert.-(http://www.gilead.com/pdf/viread_pi.pdf -Accessed [January 23, 2007].
51. Kearney B., Flaherty J., Shah J. - Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. - Clin. Pharmacokinet., 43, 595-612, 2004.
52. Antoniou T., Park-Wyllie L., Tseng A. - Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. - Pharmacotherapy, 23, 29-43, 2003.
53. Clercq E. DE-Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. - Biochem. Pharmacol., 42, 963-972, 1991.
54. Clercq E. DE - Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. - Clin. Microbiol. Rev., 16, 2003.
55. Clercq E. DE - Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. - Expert Rev. Anti-infect. Ther., 1, 21-43, 2003.
56. Robbins B., Srinivas R., Kim C., Bischofberger N., Fridland A. - Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug otthe acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(ispropyloxymethylcarbonyl)PMPA. - Antimicrob. Agents Chemother., 42, 612-617, 1998.
57. Suo Z., Johnson K. - Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. - J. Biol. Chem., 273, 27250-27258, 1998.
58. Cherrington J., Allen S., Bischofberger N., Chen M. - Kinetic interaction of the diphosphate of 9-(2-phosphonylmethoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β and γ. - Antivir. Chem. Chemother., 6, 217-221, 1995.
59. Birkus G., Hajek M., Kramata P., Votruba I., Holy A., Otova B. - Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerase α, δ, and ε*. - Antimicrob. Agents Chemother., 46, 1610-1613, 2002.
60. Birkus G., Hitchcock M., Cihlar T. - Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. - Antimicrob. Agents Chemother., 46, 716-723, 2002.
61. Robbins B., Wilcox C., Fridland A., Rodman J. - Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. - Pharamacotherapy, 23, 695-701, 2003.
62. Holy A. - Antiviral acyclic nucleoside phosphonates structure activity studies. - Antiviral Res., 71, 248-253, 2006.
63. Shaw J., Suekoka C., Oliyai R., Lee W., Arimilli M., Kim C., Cundy K. - Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. - Pharm. Res., 14, 1824-1829, 1997.
64. Arimilli M., Kim C., Dougherty J., Mulato A., Oliyai R., Shaw J., Cundy K., Bischofberger N. - Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy) propyl]adenine (PMPA) prodrugs. - Antivir. Chem. Chemother., 8, 557-564, 1997.
65. Naesens L., Bischofberger N., Augustijns P., Annaert P., Van Den Mooter G., Arimilli M., Kim C., De Clercq E. - Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbon yloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. - Antimicrob. Agents Chemother., 42, 1568-1573, 1998.
66. Barditch-Crovo P., Deeks S., Collier A., Safrin S., Coakley D., Miller M., Kearney B., Coleman R., Lamy R, Kahn J., Mcgowan I., Lietman P. - Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. - Antimicrob. Agents Chemother., 45, 2733-2739, 2001.
67. Van Gelder J., Deferme S., Naesens L., De Clercq E., Van Den Mooter G., Kinget R., Augustijns P. - Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. - Drug Metab. Dispos., 30, 924-930, 2002.
68. Cihlar T., Rosenberg I., Votruba I., Holy A. - Transport of 9-(2-phosphonomethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated. - Antimicrob. Agents Chemother., 39, 117-124, 1995.
69. Deeks S., Barditch-Crovo P., Lietman P., Hwang F., Cundy K., Rooney J., Hellmann N., Safrin S., Kahn J. - Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. - Antimicrob. Agents Chemother., 42, 2380-2384, 1998.
70. Anthonypillai C., Gibbs J., Thomas S. - The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. - Cerebrospinal Fluid Res., 3, 1-10, 2006.
71. Robbins B., Fridland A. - Metabolism and therapeutic activity of acyclic adenine phosphonate analogs. - Int. Antivir. News, 4, 57-59, 1996.
72. Tuske S., Sarafianos S., Clark A., Ding J., Naeger L., White K., Miller M., Gibbs C., Boyer P., Clark P., Wang G., Gaffney B., Jones R., Jerina D., Hughes S., Arnold E. - Structure of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. - Nat. Struct. Mol. Biol., 11, 469-474, 2004.
73. Tuske S., Sarafianos S., Clark A., Ding J., Naeger L., Miller M., Gibbs C., Jerina D., Hughes S., Arnold E. - Crystal structure of HIV-1 RT with template-primer terminated with acyclic nucleotide RT inhibitor tenofovir suggests mechanisms of evading resistance. - 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb 24-28, 2002.
74. Van Rampay K., Cherrington J., Marthas M., Berardi C., Mulato A., Spinner A., Tarara R., Canfield D., Telm S., Bischofberger N., Pedersen N. - 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. - Antimicrob. Agents Chemother., 40, 2586-2591, 1996.
75. McColl D., Margot N., Wulfsohn M., Coakley D., Cheng A., Miller M. - Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. - J. Acquir. Immune Defic. Syndr., 37, 1340-1350, 2004.
76. Wainberg M., Miller M., Quan Y., Salomon H., Mulato A., Lamy P., Margot N., Anton K., Cherrington J. - In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. - Antivir. Ther., 4, 87-94, 1999.
77. Meyer P., Matsuura S., So A., Scott W. - Unblocking of chain-terminated primer by HIV- reverse transcriptase through a nucleotide-dependent mechanism. - Proc. Natl. Acad. Sci., 95, 13471-13476, 1998.
78. Singh Y., Palombo M. Sinko. - Recent trends in targeted anti-cancer prodrug and conjugate design. - Curr. Med. Chem., 15, 1802-1826, 2008.
79. Kratz F., Muller I.; Ryppa C., Warnecke A. - Prodrug strategies in anticancer chemotherapy - ChemMedChem, 3, 20-53, 2008.
80. Meares C. (Ed.) - Perspectives in Bioconjugate Chemistry. - American Chemical Society, Washington DC, 1993, pp. 1-8.
81. Sinko P., Kunta J., Usansky H., Perry B. - Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. - J. Pharmacol. Exp. Ther., 46, 359-366, 2004.
82. Su Y., Zhang X., Sinko P. - Human organic anion-transporting polypeptide OATP-A (SLC21α3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. - Mol. Pharm., 1, 49-56, 2004.
83. Usansky H., Hu P., Sinko, P. - Differential roles of P-glycoprotein multidrug resistance associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. - Drug Metab. Dispos., 36, 863-869, 2008.
84. Williams G., Liu A., Knipp G., Sinko P. - Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporters (MRP2). - Antimicrob. Agents Chemother., 46, 3456-3462, 2002.
85. Farese-Di Giorgio A., Rouquayrol M., Greiner J., Aubertin A., Vierling P., Guedj R. - Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir. - Antivir. Chem. Chemother., 11, 97-110, 2000.
86. Rouquayrol M., Gaucher B., Greiner J., Aubertin A., Vierling P., Guedj R. - Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir. - Carbohydr. Res., 336, 161-180, 2001.
87. Gunaseelan S., Debrah O., Wan L., Leibowitz M., Rabson A., Stein S., Sinko P. - Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. - Bioconj. Chem., 15, 1322-1333, 2004.
88. Zhang X., Wan L., Pooyan S., Su Y., Gardner C., Leibowitz M., Sinko P. - Quantitative assessment of the cell penetrating properties of R.I.-Tat-9: evidence for a cell type-specific barrier at the plasma membrane of epithelial cells. - Mol. Pharm., 1, 145-155, 2004.
89. Ramanathan S., Pooyan S., Stein S., Prasad P., Wang J., Leibowitz M., Ganapathy V., Sinko P. - Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide. - Pharm. Res., 18, 950-956, 2001.
90. Ramanathan S., Qiu B., Pooyan S., Zhang G., Stein S., Leibowitz M., Sinko P. - Targeted PEG-based bioconjugates enhance the cellular uptake and transport of HIV-1 TAT nonapeptide. - J. Control. Release, 77, 199-212, 2001.
91. Wan L., Zhang X., Gunaseelan S., Pooyan S., Debrah O., Leibowitz M., Rabson A., Stein S., Sinko P. - Novel multi-component nanopharmaceuticals derived from poly(ethylene)glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. - AIDS Res. Ther., 3, 12-26, 2006.
92. Schuitemaker H., Kootstra N., De Goede R., DeWolf F., Miedema F., Tersmette M. - Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. - J. Virol., 65, 356-363, 1991.
93. Weissleder R., Kelly K, Sun E., Shtatland T., Josephson L. - Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. - Nat. Biotechnol., 11, 1418-1423, 2005.
94. Auger M., Ross J. - In: The Natural Immune System: The Macrophage, Lewis C.E., McGee J.O. (Eds.), Oxford University Press, New York, 1992, pp. 2-74
95. Fridkin M., Tsuberry H., Tzehoval E., Vonsover A., Biondi L., Filira R., Rocchi R. - Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy. - J. Peptide Sci., 11, 37-44, 2005.
96. Pooyan S., Qiu B., Chan M., Fong D., Sinko P., Leibowitz M., Stein S. - Conjugates bearing multiple formyl-methionyl peptides display enhanced binding to but not activation of phagocytic cells. - Bioconj. Chem., 13, 216-223, 2002.
97. Prossnitz E., Ye R. -The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. - Pharmacol. Ther., 74, 73-102, 1997.
98. Wan L., Zhang X., Pooyan S., Palombo M., Leibowitz M., Stein S., Sinko P. - Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages. - Bioconj. Chem., 19, 28-38, 2008.
99. Nakai T., Kanamori T., Sando S., Ayoma Y. - Remarkably size-regulated cell invasion by artificial viruses: saccharide-dependent self-aggregation of glycoviruses and its consequence in glycoviral gene delivery. - J. Am. Chem. Soc., 125, 8465-8475, 2003.
100. Osaki F., Kanomori T., Sando S., Sera T., Ayoma Y. - A quantum dot conjugated sugar ball and its cellular uptake: on the size effects of endocytosis in the subviral region. - J. Am. Chem. Soc., 126, 6520-6521, 2004.
101. Desai M., Labhesetwar V., Walter E., Levy R., Amidon G. - The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. - Pharm. Res., 14, 1568-1573, 1997.
102. Prabha S., Zhou W., Panyam J., Labhasetwar V. - Size-dependency of nanoparticle-mediated gene transfection with fractioned nanoparticles. - Int. J. Pharm., 244, 105-115, 2002.
103. Wan L., Pooyan S., Hu S., Leibowitz M., Stein S., Sinko P. - Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formylmethionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. - Pharm. Res., 24, 2100-2119, 2007.